The emergence of novel pharmacological treatments, particularly GLP-1 receptor agonists such as semaglutide and dual incretin receptor agonists like tirzepatide, represents one of the most significant developments in obesity management in recent decades [29]. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.